Q BioMed (Q BioMed) Float Percentage Of Total Shares Outstanding : 97.41% (As of May. 03, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Q BioMed Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Q BioMed's float shares is 141.33 Mil. Q BioMed's total shares outstanding is 145.09 Mil. Q BioMed's float percentage of total shares outstanding is 97.41%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Q BioMed's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Q BioMed's Institutional Ownership is 0.00%.

Q BioMed Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Q BioMed's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	141.33	/	145.09
	=	97.41%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q BioMed (Q BioMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

C/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017

Website

https://www.qbiomed.com

Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.

Executives

William S Rosenstadt	director, 10 percent owner, officer: Chief Legal Officer	ORTOLI ROSENSTADT LLP, 501 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Denis Corin	director, 10 percent owner, officer: Chief Executive Officer	10 MARKET STREET, SUITE 427, GRAND CAYMAN E9 KY1-9006
Rick Panicucci	director	501 MADISON STREET, 14TH FLOOR, NEW YORK NY 10022
Alan P Lindsay	10 percent owner	580 HORNBY STREET, FIFTH FLOOR, VANCOUVER BC CANADA V6C 2E7 A1